Wealth Enhancement Advisory Services LLC Raises Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Wealth Enhancement Advisory Services LLC grew its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 31.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,268 shares of the company’s stock after purchasing an additional 3,847 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Xeris Biopharma were worth $55,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Xeris Biopharma by 106.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company’s stock worth $581,000 after buying an additional 88,224 shares during the period. Vanguard Group Inc. increased its stake in shares of Xeris Biopharma by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock worth $26,778,000 after purchasing an additional 133,738 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Xeris Biopharma by 10.5% during the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company’s stock worth $384,000 after purchasing an additional 10,748 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Xeris Biopharma during the 4th quarter valued at about $45,000. Finally, Millennium Management LLC grew its stake in Xeris Biopharma by 34.8% during the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company’s stock valued at $6,606,000 after acquiring an additional 502,853 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Xeris Biopharma from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum boosted their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a report on Friday, March 7th. Finally, Oppenheimer boosted their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $6.25.

Xeris Biopharma Price Performance

XERS opened at $4.58 on Thursday. The stock has a market capitalization of $716.22 million, a PE ratio of -15.27 and a beta of 0.71. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.03 and a 12-month high of $6.07. The firm’s fifty day moving average price is $4.56 and its 200 day moving average price is $4.14.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. On average, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Kevin Mcculloch bought 25,000 shares of the company’s stock in a transaction on Friday, June 13th. The shares were bought at an average cost of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider now owns 1,708,585 shares of the company’s stock, valued at approximately $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.47% of the stock is owned by corporate insiders.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.